ClinicalTrials.gg
WithdrawnNCT04621331Updated Jul 5, 2022

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

A Phase 3 interventional study of Roxadustat in Anemia Associated With Chronic Kidney Disease, sponsored by FibroGen. Withdrawn at 4 sites in United States. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-07-05.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
43rd of 43
0 · median 154
Started
2022
with 1 other
Phase 3
25 of 43
1 open now
Registered
32nd of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 43rd largest by enrollment, is one of 2 that started in 2022, is one of 25 in phase 3, and was the 32nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD of roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as well as end-stage renal disease (ESRD) who are receiving either hemodialysis (HD) or peritoneal dialysis (PD). The study will enroll patients between the ages of 2 to \<18 years in two sequential cohorts, with the older cohort of ages 12 to \<18 years enrolled first. Approximately 30 patients will be enrolled in each age-based cohort.

03

Conditions studied

  • Anemia Associated With Chronic Kidney Disease

Keywords

  • Anemia, Chronic Kidney Disease (CKD)
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Important Inclusion Criteria:

  • Clinically stable CKD in the opinion of the investigator.
  • Estimated (Bedside Schwartz formula) of \< 60 ml/min/1.73 m2 (stage 3, 4 and 5 CKD) for non-dialysis patients, or patients who are receiving chronic dialysis (hemodialysis or peritoneal dialysis) for ESRD.
  • For ESA-naïve patients (either NDD or DD; ESA-naïve is defined as those patients whose total duration of prior ESA exposure is ≤ 3 weeks within the preceding 12 weeks at the time is obtained), mean of two most recent central laboratory values during the screening period obtained at least 2 days apart must be \< 11.0 g/dL. For patients currently receiving stable ESA dosing who will discontinue ESA and convert to roxadustat during study, mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be ≥ 10.0 g/dL and ≤ 12.5 g/dL.
  • Ferritin >50 ng/mL and transferrin saturation >10% (obtained from screening visit).
  • (ALT) and aspartate aminotransferase (AST) ≤ 2x (ULN) and total (Tbili) ≤1.5x ULN at randomization (obtained from screening visit).
  • Serum folate and vitamin B12 > LLN (obtained from screening visit).

Important Exclusion Criteria:

  • Uncontrolled hypertension as judged by the principal investigator in the 2 weeks prior to screening.
  • Known hematologic disease other than anemia associated with CKD.
  • Known within the past 5 years before screening.
  • Any prior organ transplant or any planned organ transplant during the study period.
  • Any RBC transfusion during the past 8 weeks before screening.
  • Any condition leading to significant blood loss (e.g., gastrointestinal bleeding, surgical procedures) within 8 weeks before screening or during the screening period.
  • History of chronic liver disease.
  • Pure red cell aplasia (PRCA) or history of PRCA.
  • History of epileptic seizures.
  • History of hyperlipidemia or significant thrombotic/thromboembolic event (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction).
  • History of thrombosis of an arteriovenous fistula/graft within 12 weeks prior to enrollment.
  • Any active systemic or significant infection or episode of peritonitis within 30 days of screening.
  • Any statin use within 30 days of screening.
  • Any prior exposure to roxadustat or any other HIF-PH inhibitor.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Starting doses of 20, 50, 70 or 100 mg based on weight.

    Drug: Roxadustat

Interventions

  • HIF-PH inhibitor for treatment of anemia in CKD

    Also known as: FG-4592

06

What researchers measure

Primary outcomes

  1. Proportion of patients with mean Hb ≥ 11.0 g/dL

    Time frame: Averaged over weeks 16-24

Secondary outcomes

  1. Mean change in Hb

    Time frame: Baseline to averaged over weeks 16-24

  2. Time to first Hb response (this only applies to NDD patients)

    Time frame: From baseline without rescue therapy

07

Study locations

4 sites
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
    New York, New York 10029, United States
  • Investigative site
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in May 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2020
First posted
Nov 9, 2020
StartActual
May 23, 2022
Primary completionActual
May 23, 2022
CompletionActual
May 23, 2022
Last update
Jul 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04621331
Lead sponsor
FibroGen
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
May 23, 2022
Primary completion
May 23, 2022
Completion
May 23, 2022
Last update
Jul 5, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion